BidaskClub lowered shares of FibroGen (NASDAQ:FGEN) from a strong-buy rating to a buy rating in a research report released on Friday morning, BidAskClub reports.

A number of other analysts have also recently issued reports on FGEN. Goldman Sachs Group reissued a neutral rating and issued a $45.00 target price on shares of FibroGen in a research report on Wednesday, May 29th. Zacks Investment Research raised FibroGen from a hold rating to a buy rating and set a $51.00 target price for the company in a research report on Tuesday. Mizuho reissued a buy rating and issued a $65.00 target price on shares of FibroGen in a research report on Sunday, August 11th. ValuEngine cut FibroGen from a buy rating to a hold rating in a research report on Saturday, August 10th. Finally, Piper Jaffray Companies reissued a positive rating and issued a $40.00 target price (down from $65.00) on shares of FibroGen in a research report on Monday, May 27th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. FibroGen presently has a consensus rating of Buy and an average target price of $61.00.

Shares of FGEN traded up $1.46 during mid-day trading on Friday, reaching $44.60. The company’s stock had a trading volume of 566,600 shares, compared to its average volume of 561,353. FibroGen has a 12-month low of $33.51 and a 12-month high of $62.00. The stock has a market cap of $3.77 billion, a PE ratio of -43.30 and a beta of 1.86. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.73 and a quick ratio of 6.16. The company’s 50 day moving average is $45.84 and its 200 day moving average is $47.95.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $1.75. FibroGen had a return on equity of 9.01% and a net margin of 13.90%. The business had revenue of $191.57 million for the quarter, compared to the consensus estimate of $29.03 million. During the same quarter in the prior year, the business posted ($0.28) EPS. The business’s revenue for the quarter was up 335.9% on a year-over-year basis. As a group, sell-side analysts anticipate that FibroGen will post -0.37 EPS for the current fiscal year.

In other FibroGen news, SVP Christine Chung sold 11,250 shares of the stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $44.05, for a total transaction of $495,562.50. Following the completion of the sale, the senior vice president now directly owns 157,195 shares of the company’s stock, valued at approximately $6,924,439.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $35.37, for a total value of $1,401,925.32. Following the sale, the chief executive officer now directly owns 2,503,912 shares of the company’s stock, valued at $88,563,367.44. The disclosure for this sale can be found here. Insiders have sold a total of 266,574 shares of company stock valued at $11,306,256 over the last ninety days. 8.96% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Lindbrook Capital LLC lifted its position in FibroGen by 150.0% during the 1st quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 300 shares during the period. FTB Advisors Inc. acquired a new stake in FibroGen during the 1st quarter worth approximately $27,000. Manchester Capital Management LLC purchased a new position in shares of FibroGen during the 1st quarter worth approximately $39,000. Cornerstone Advisors Inc. raised its stake in shares of FibroGen by 672.8% during the 1st quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 693 shares in the last quarter. Finally, Quadrant Capital Group LLC purchased a new position in shares of FibroGen during the 1st quarter worth approximately $45,000. 64.67% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Further Reading: How is the Producer Price Index calculated?

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.